Patent Grant
9370418
The present invention generally relates to prosthetic valves for implantation in body channels. More particularly, the present invention relates to unitary surgical prosthetic heart valves configured to be surgically implanted in less time than current valves, and associated valve delivery systems.
In vertebrate animals, the heart is a hollow muscular organ having four pumping chambers as seen in
The atria are the blood-receiving chambers, which pump blood into the ventricles. The ventricles are the blood-discharging chambers. A wall composed of fibrous and muscular parts, called the interatrial septum separates the right and left atria (see
The synchronous pumping actions of the left and right sides of the heart constitute the cardiac cycle. The cycle begins with a period of ventricular relaxation, called ventricular diastole. The cycle ends with a period of ventricular contraction, called ventricular systole. The four valves (see
Various surgical techniques may be used to repair a diseased or damaged valve. In a valve replacement operation, the damaged leaflets are excised and the annulus sculpted to receive a replacement valve. Due to aortic stenosis and other heart valve diseases, thousands of patients undergo surgery each year wherein the defective native heart valve is replaced by a prosthetic valve, either bioprosthetic or mechanical. Another less drastic method for treating defective valves is through repair or reconstruction, which is typically used on minimally calcified valves. The problem with surgical therapy is the significant insult it imposes on these chronically ill patients with high morbidity and mortality rates associated with surgical repair.
When the valve is replaced, surgical implantation of the prosthetic valve typically requires an open-chest surgery during which the heart is stopped and patient placed on cardiopulmonary bypass (a so-called “heart-lung machine”). In one common surgical procedure, the diseased native valve leaflets are excised and a prosthetic valve is sutured to the surrounding tissue at the valve annulus. Because of the trauma associated with the procedure and the attendant duration of extracorporeal blood circulation, some patients do not survive the surgical procedure or die shortly thereafter. It is well known that the risk to the patient increases with the amount of time required on extracorporeal circulation. Due to these risks, a substantial number of patients with defective valves are deemed inoperable because their condition is too frail to withstand the procedure. By some estimates, about 30 to 50% of the subjects suffering from aortic stenosis who are older than 80 years cannot be operated on for aortic valve replacement.
Because of the drawbacks associated with conventional open-heart surgery, percutaneous and minimally-invasive surgical approaches are garnering intense attention. In one technique, a prosthetic valve is configured to be implanted in a much less invasive procedure by way of catheterization. For instance, U.S. Pat. No. 5,411,552 to Andersen et al. describes a collapsible valve percutaneously introduced in a compressed state through a catheter and expanded in the desired position by balloon inflation. Although these remote implantation techniques have shown great promise for treating certain patients, replacing a valve via surgical intervention is still the preferred treatment procedure. One hurdle to the acceptance of remote implantation is resistance from doctors who are understandably anxious about converting from an effective, if imperfect, regimen to a novel approach that promises great outcomes but is relatively foreign. In conjunction with the understandable caution exercised by surgeons in switching to new techniques of heart valve replacement, regulatory bodies around the world are moving slowly as well. Numerous successful clinical trials and follow-up studies are in process, but much more experience with these new technologies will be required before they are completely accepted.
Accordingly, there is a need for an improved device and associated method of use wherein a prosthetic valve can be surgically implanted in a body channel in a more efficient procedure that reduces the time required on extracorporeal circulation. It is desirable that such a device and method be capable of helping patients with defective valves that are deemed inoperable because their condition is too frail to withstand a lengthy conventional surgical procedure.
Furthermore, surgeons relate that one of the most difficult tasks when attempting minimally invasive heart valve implantation or implantation through a small incision is tying the suture knots that hold the valve in position. A typical aortic valve implant utilizes 12-24 sutures (commonly 15) distributed evenly around and manually tied on one side of the sewing ring. The knots directly behind the commissure posts of a prosthetic aortic valve are particularly challenging because of space constraints. Eliminating the need to tie suture knots or even reducing the number of knots to those that are more accessible would greatly facilitate the use of smaller incisions that reduces infection risk, reduces the need for blood transfusions and allows more rapid recovery compared to patients whose valves are implanted through the full sternotomy commonly used for heart valve implantation.
The present invention addresses these needs and others.
Various embodiments of the present application provide prosthetic valves and methods of use for replacing a defective native valve in a human heart. Certain embodiments are particularly well adapted for use in a surgical procedure for quickly and easily replacing a heart valve while minimizing time using extracorporeal circulation (i.e., bypass pump).
In one embodiment, a method for treating a native aortic valve in a human heart to replace the function of the aortic valve, comprises: 1) accessing a native valve through an opening in a chest; 2) placing guiding sutures in the annulus 3) advancing a heart valve within a lumen of the annulus; and 4) plastically expanding a metallic anchoring skirt on the heart valve to mechanically couple to the annulus in a quick and efficient manner.
The native valve leaflets may be removed before delivering the prosthetic valve. Alternatively, the native leaflets may be left in place to reduce surgery time and to provide a stable base for fixing the anchoring skirt within the native valve. In one advantage of this method, the native leaflets recoil inward to enhance the fixation of the metallic anchoring skirt in the body channel. When the native leaflets are left in place, a balloon or other expansion member may be used to push the valve leaflets out of the way and thereby dilate the native valve before implantation of the anchoring skirt. The native annulus may be dilated between 1.0-5 mm from their initial orifice size to accommodate a larger sized prosthetic valve.
In accordance with a preferred aspect, a heart valve includes a prosthetic valve defining therein a non-expandable, non-collapsible orifice, and an expandable anchoring skirt extending from an inflow end thereof. The anchoring skirt has a contracted state for delivery to an implant position and an expanded state configured for outward connection to the surrounding annulus. Desirably, the anchoring skirt is plastically expandable.
In one preferred form, a prosthetic heart valve for implant at a heart valve annulus comprise a non-expandable, non-collapsible annular support structure defining a flow orifice and having an inflow end. Valve leaflets attach to the support structure and are mount to alternately open and close across the flow orifice. A plastically-expandable stent frame has a first end extending around the flow orifice and connected to the valve at the inflow end of the support structure. The stent frame has a second end projecting in the inflow direction away from the support structure and is capable of assuming a contracted state for delivery to an implant position and a wider expanded state for outward contact with an annulus. The stent frame has an undulating first end with peaks and valleys that conform to a similar shape of the inflow end of the support structure, and the stent frame in the contracted state extends away from the inflow end of the support structure in a tubular portion between the peaks and valleys and then angles inward in a conical portion to the second end. In one embodiment, the stent frame angles inward in a conical portion in the contracted state and the second end defines an orifice that is non-circular, such as by non-uniform crimping.
In another aspect, a prosthetic heart valve for implant at a heart valve annulus, comprises:
Preferably, the support structure includes a plurality of commissure posts projecting in an outflow direction, and the valve leaflets are flexible and attached to the support structure and commissure posts and mounted to alternately open and close across the flow orifice. Also, a sealing ring desirably circumscribes an inflow end of the support structure. The enlarged sealing flange surrounding the second end of the plastically-expandable stent frame is spaced from the suture permeable ring to help conform the stent frame to the aortic annulus.
In one embodiment, the heart valve comprises a commercially available prosthetic valve having a sewing ring, and the anchoring skirt attaches to the sewing ring. The contracted state of the anchoring skirt may be conical, tapering inward from the first end toward the second end, while in the expanded state the stent frame is conical but tapering outward from the first end toward the second end. The anchoring skirt preferably comprises a plurality of radially expandable struts at least some of which are arranged in rows, wherein the distalmost row has the greatest capacity for expansion from the contracted state to the expanded state. The sewing ring may comprise a solid yet compressible material that is relatively stiff so as to provide a seal against the annulus and has a concave inflow shape that conforms to the annulus.
A method of delivery and implant of a prosthetic heart valve system is also disclosed herein, comprising the steps of:
The method may involve increasing the orifice size of the heart valve annulus by 1.0-5.0 mm by plastically expanding the stent frame. In one embodiment, the prosthetic valve of the valve component is selected to have an orifice size that matches the increased orifice size of the heart valve annulus.
One embodiment of the method further includes mounting the heart valve on a holder having a proximal hub and lumen therethrough. The holder mounts on the distal end of a handle shaft having a lumen therethrough, and the method includes passing a balloon catheter through the lumen of the handle shaft and the holder and within the heart valve, and inflating a balloon on the balloon catheter to expand the anchoring skirt. The heart valve mounted on the holder may be packaged separately from the handle shaft and the balloon catheter. Desirably, the contracted state of the expandable stent frame/anchoring skirt is conical, and the balloon on the balloon catheter has a larger distal expanded end than its proximal expanded end so as to apply expansion deflection to the anchoring skirt and not to the prosthetic valve. In a preferred embodiment, the balloon distal and proximal diameters are essentially the same, the balloon being generally symmetric across an axial midline, and the balloon midline is positioned near the distal end of the stent frame prior to inflation. The delivery system including the valve holder is designed to position the balloon within the heart valve so that it inflates within the anchoring skirt, and not within the actual valve components.
Preferably, a valve delivery system includes an integrated balloon catheter and tubular handle shaft through which the catheter extends. A distal end of the handle shaft includes an adapter which mates with a holder of the heart valve, and a locking sleeve for rapidly connecting the delivery system to the heart valve holder. A balloon of the balloon catheter resides within the adapter and may be advanced distally into position for expanding the anchoring skirt. A tubular balloon introducer sleeve attached when removing the heart valve from a storage jar facilitates passage of the balloon through the heart valve.
A further understanding of the nature and advantages of the present invention are set forth in the following description and claims, particularly when considered in conjunction with the accompanying drawings in which like parts bear like reference numerals.
The invention will now be explained and other advantages and features will appear with reference to the accompanying schematic drawings wherein:
The present invention attempts to overcome drawbacks associated with conventional, open-heart surgery, while also adopting some of the techniques of newer technologies which decrease the duration of the treatment procedure. The prosthetic heart valves of the present invention are primarily intended to be delivered and implanted using conventional surgical techniques, including the aforementioned open-heart surgery. There are a number of approaches in such surgeries, all of which result in the formation of a direct access pathway to the particular heart valve annulus. For clarification, a direct access pathway is one that permits direct (i.e., naked eye) visualization of the heart valve annulus. In addition, it will be recognized that embodiments of the prosthetic heart valves described herein may also be configured for delivery using percutaneous approaches, and those minimally-invasive surgical approaches that require remote implantation of the valve using indirect visualization. However, the latter two approaches—percutaneous and minimally-invasive—invariably rely on collapsible/expandable valve constructs. And, while certain aspects described herein could be useful for such valves and techniques, the primary focus and main advantages of the present application is in the realm of non-expandable “surgical” valves introduced in conventional manners.
One primary aspect of the present invention is a “unitary” prosthetic heart valve in which a tissue anchor is implanted at the same time as a valve member resulting in certain advantages. The exemplary unitary prosthetic heart valve of the present invention is a hybrid valve member, if you will, with both non-expandable and expandable portions. By utilizing an expandable anchoring skirt or stent coupled to a non-expandable valve member, the duration of the anchoring operation is greatly reduced as compared with a conventional sewing procedure utilizing an array of sutures. The expandable anchoring skirt may simply be radially expanded outward into contact with the implantation site, or may be provided with additional anchoring means, such as barbs. As stated, conventional open-heart approach and cardiopulmonary bypass familiar to cardiac surgeons are used. However, due to the expandable anchoring skirt, the time on bypass is greatly reduced by the relative speed of implant in contrast to the previous time-consuming knot-tying process.
For definitional purposes, the terms “stent” or “coupling stent” refer to a structural component that is capable of anchoring to tissue of a heart valve annulus. The coupling stents described herein are most typically tubular stents, or stents having varying shapes or diameters. A stent is normally formed of a biocompatible metal frame, such as stainless steel or Nitinol. More preferably, in the context of the present invention the stents are made from laser-cut tubing of a plastically-expandable metal. Other coupling stents that could be used with valves of the present invention include rigid rings, spirally-wound tubes, and other such tubes that fit tightly within a valve annulus and define an orifice therethrough for the passage of blood. It is entirely conceivable, however, that the coupling stent could be separate clamps or hooks that do not define a continuous periphery. Although such devices sacrifice some contact uniformity, and speed and ease of deployment, they could be configured to work in conjunction with a particular valve member.
A distinction between self-expanding and balloon-expanding stents exists in the field. A self-expanding stent may be crimped or otherwise compressed into a small tube and possesses sufficient elasticity to spring outward by itself when a restraint such as an outer sheath is removed. In contrast, a balloon-expanding stent is made of a material that is substantially less elastic, and indeed must be plastically expanded from the inside out when converting from a contracted to an expanded diameter. It should be understood that the term balloon-expanding stents encompasses plastically-expandable stents, whether or not a balloon is used to actually expand it (e.g., a device with mechanical fingers could expand the stent). The material of the stent plastically deforms after application of a deformation force such as an inflating balloon or expanding mechanical fingers. Consequently, the term “balloon-expandable stent” should be understood as referring to the material or type of the stent as opposed to the specific expansion means.
The term “valve member” refers to that component of a heart valve that possesses the fluid occluding surfaces to prevent blood flow in one direction while permitting it in another. As mentioned above, various constructions of valve members are available, including those with flexible leaflets and those with rigid leaflets, or even a ball and cage arrangement. The leaflets may be bioprosthetic, synthetic, metallic, or other suitable expedients. In a preferred embodiment, the non-expandable valve member is an “off-the-shelf” standard surgical valve of the type that has been successfully implanted using sutures for many years, such as the Carpentier-Edwards PERIMOUNT Magna® Aortic Heart Valve available from Edwards Lifesciences of Irvine, Calif., though the autonomous nature of the valve member is not absolutely required. In this sense, a “off-the-shelf” prosthetic heart valve is suitable for stand-alone sale and use, typically including a non-expandable, non-collapsible support structure having a sewing ring capable of being implanted using sutures through the sewing ring in an open-heart, surgical procedure.
A primary focus of the present invention is a prosthetic heart valve having a single stage implantation in which a surgeon secures a hybrid valve having an anchoring skirt and valve member to a valve annulus as one unit or piece (e.g., a “unitary” valve). Certain features of the hybrid anchoring skirt and valve member are described in U.S. Pat. No. 8,308,798, filed Dec. 10, 2009, the contents of which are expressly incorporated herein. It should be noted that “two-stage” prosthetic valve delivery disclosed in the aforementioned publication refers to the two primary steps of a) anchoring structure to the annulus, and then b) connecting a valve member, which does not necessarily limit the valve to just two parts. Likewise, the valve described herein is especially beneficial in a single stage implant procedure, but that does not necessarily limit the overall system to just one part. For instance, the heart valve disclosed herein could also use an expanding base stent which is then reinforced by the subsequently implanted heart valve. Because the heart valve has a non-expandable and non-collapsible annular support structure, and a plastically-expandable anchoring skirt, it effectively resists recoil of a self-expanded base stent. That said, various claims appended hereto may exclude more than one part.
As a point of further definition, the term “expandable” is used herein to refer to a component of the heart valve capable of expanding from a first, delivery diameter to a second, implantation diameter. An expandable structure, therefore, does not mean one that might undergo slight expansion from a rise in temperature, or other such incidental cause such as fluid dynamics acting on leaflets or commissures. Conversely, “non-expandable” should not be interpreted to mean completely rigid or a dimensionally stable, as some slight expansion of conventional “non-expandable” heart valves, for example, may be observed.
In the description that follows, the term “body channel” is used to define a blood conduit or vessel within the body. Of course, the particular application of the prosthetic heart valve determines the body channel at issue. An aortic valve replacement, for example, would be implanted in, or adjacent to, the aortic annulus. Likewise, a mitral valve replacement will be implanted at the mitral annulus. Certain features of the present invention are particularly advantageous for one implantation site or the other, in particular the aortic annulus. However, unless the combination is structurally impossible, or excluded by claim language, any of the heart valve embodiments described herein could be implanted in any body channel.
A “quick-connect” aortic valve bio-prosthesis described herein is a surgically-implanted medical device for the treatment of aortic valve stenosis. The exemplary quick-connect device comprises an implantable bio-prosthesis and a delivery system for its deployment. The device, delivery system and method of use take advantage of the proven hemodynamic performance and durability of existing commercially available, non-expandable prosthetic heart valves, while improving ease of use and reducing total procedure time. This is mainly accomplished by eliminating the need to suture the bio-prosthesis onto the native annulus as is currently done per standard surgical practice, and typically requires 12-24 manually-tied sutures around the valve perimeter. Also, the technique may obviate the need to excise the leaflets of the calcified valve and debride or smooth the valve annulus.
An exemplary hybrid prosthetic heart valve and valve holder is disclosed in U.S. Patent Publication No. 2012/0065729 to Pintor, et al., filed Jun. 23, 2011, to which priority is claimed, and which is hereby expressly incorporated by reference herein.
In one embodiment, the valve member 24 comprises a Carpentier-Edwards PERIMOUNT Magna® Aortic Heart Valve available from Edwards Lifesciences of Irvine, Calif., while the anchoring skirt 26 includes an inner plastically-expandable frame or stent covered with fabric. In another embodiment, the valve member 24 comprises a PERIMOUNT Magna® Aortic valve subjected to GLX tissue treatment, which allows for dry packaging and sterilization and eliminates the need to rinse the valves before implantation.
The general function of the anchoring skirt 26 is to provide the means to attach the prosthetic valve member 24 to the native aortic root. This attachment method is intended as an alternative to the present standard surgical method of suturing aortic valve bio-prostheses to the aortic valve annulus, and is accomplished in much less time. Further, this attachment method improves ease of use by eliminating most if not all suturing. The anchoring skirt 26 may be a pre-crimped, tapered, 316L stainless steel balloon-expandable stent, desirably covered by a polyester fabric to help seal against paravalvular leakage and promote tissue ingrowth once implanted within the annulus.
The completed valve member 24 provides the occluding surfaces for the prosthetic heart valve 20, preferably in the form of flexible bioprosthetic leaflets. For example, the valve leaflets may be taken from another human heart (cadaver), a cow (bovine), a pig (porcine valve) or a horse (equine). Alternatively, the valve member may comprise mechanical components rather than biological tissue. Although an autonomous (i.e., capable of stand-alone surgical implant) flexible leaflet valve member 24 is described and illustrated, alternative valve members that have rigid leaflets, or are not fully autonomous may be substituted.
For bioprosthetic valves, an exemplary process includes storing the prosthetic heart valve 20 in a preservative solution after manufacture and prior to use. A preservative such as glutaraldehyde is provided within a storage jar. This “wet” storage arrangement applies to the illustrated heart valve 20 shown, which includes conventional bioprosthetic leaflets. However, as mentioned above, the heart valve could also be used without a preservative solution for bioprosthetic leaflets that have been dried, such as with the GLX tissue treatment from Edwards Lifesciences, and also for mechanical valves.
The valve holder 22, as seen in the details of
In one embodiment, the holder 22 is formed of a rigid polymer such as Delrin polypropylene that is transparent to increase visibility of an implant procedure. As best seen in
An exemplary implant procedure for the prosthetic heart valve 20 is summarized with reference to in
In the ensuing procedure drawings, the heart valve 20 is oriented with an inflow end down and an outflow end up. That is, blood flow through the valve 20 is upward as shown in the drawings. Therefore, the terms inflow side and down may be used interchangeably at times, as well as the terms outflow side and up. Furthermore, the terms proximal and distal are defined from the perspective of the surgeon delivering the valve inflow end first, and thus proximal is synonymous with up or the outflow side, and distal with down or the inflow side.
An implant procedure involves delivering the heart valve 20 and expanding the anchoring skirt 26 at the aortic annulus, and potentially tying off or securing one or more sutures. Because the valve member 24 is non-expandable, the entire procedure is typically done using the conventional open-heart technique. However, because the anchoring skirt 26 is implanted by simple expansion, with reduced suturing, the entire operation takes less time. This hybrid approach will also be much more comfortable to surgeons familiar with the open-heart procedures and commercially available heart valves.
A preliminary step in preparing an aortic annulus for receiving the heart valve includes installation of guide sutures 39. The aortic annulus is shown schematically isolated and it should be understood that various anatomical structures are not shown for clarity. The annulus includes a fibrous ring of tissue that projects inward from surrounding heart walls. The annulus defines an orifice between the ascending aorta and the left ventricle. Although not shown, native leaflets project inward at the annulus to form a one-way valve at the orifice. The leaflets may be removed prior to the procedure, or left in place as mentioned above. If the leaflets are removed, some of the calcified annulus may also be removed, such as with a rongeur. The ascending aorta commences at the annulus with three outward bulges or sinuses, two of which are centered at coronary ostia (openings) leading to coronary arteries. As will be seen below, it is important to orient the prosthetic valve member 24 so that its commissure posts 36 are not aligned with and thus not blocking the coronary ostia.
The surgeon attaches the guide sutures 39 at three evenly spaced locations around the aortic annulus. In the illustrated embodiment, the guide sutures 39 attach to locations below or corresponding to the coronary ostia (that is, two guide sutures are aligned with the ostia, and the third centered below the non-coronary sinus). The guide sutures 39 are preferably looped twice through the annulus from the outflow or ascending aorta side to the inflow or ventricular side. Of course, other suturing methods or pledgets may be used depending on surgeon preference.
The surgeon delivers a plurality of suture snares 120 down each pair of the guide sutures 39 into contact with the upper or outflow side of the sewing ring 28. The snares 120 enable downward pressure to be applied to the ring 28 and thus the valve 20 during the implant procedure, which helps insure good seating of the ring 28 on the annulus. The snares 120 also provide rigid enclosures around each of the flexible guide sutures 39 which helps avoid entanglement with other moving surgical instruments, as will be appreciated. As there are three pairs of guide sutures 39 (six free lengths) three snares 120 are utilized, though more or less is possible. The snares 120 are typically tubular straw-like members of medical grade plastic.
After distal advancement, the balloon 112 projects downward through the valve 20, and into the left ventricle. As will be explained below, the delivery system 110 provides binary position displacement of the balloon 112, either retracted substantially within the prosthetic heart valve 20 or advanced precisely as far as necessary to expand the anchoring skirt 26 of the valve.
Simple interference between the anchoring skirt 26 and the annulus may be sufficient to anchor the heart valve 20, or interacting features such as projections, hooks, barbs, fabric, etc. may be utilized. For example, a distal end of the anchoring skirt may expand more than the rest of the anchoring skirt so that peaks in the strut row farthest from the prosthetic valve project outward into the surrounding annulus. Also, the balloon 112 may have a larger distal expanded end than its proximal expanded end so as to apply more force to the free end of the anchoring skirt 26 than to the prosthetic valve member 24. In this way, the prosthetic valve member 24 and flexible leaflets therein are not subject to high expansion forces from the balloon 112.
The balloon 112 desirably is tapered to have an angle between about 0-45°, and more preferably is about 38° (0° being a cylindrical expansion). Alternatively, the balloon 112 may include curves or non-axi-symmetric contours to deform the anchoring skirt 26 to various desired shapes to fit better within the particular annulus. Indeed, various potential shapes are described in U.S. Patent Publication 2008/0021546, entitled System for Deploying Balloon-Expandable Heart Valves, published Jan. 24, 2008, the disclosure of which is expressly incorporated herein.
The next step is retraction of the balloon 112 and entire delivery system 110 from the valve holder 22 before or after removal of the snares 120, which happens only as a contingency. Although not shown, the most common procedure after expansion of the balloon 112 and skirt 26 involves the surgeon severing the connecting sutures between the valve holder 22 and the prosthetic valve member 24, and removing the entire delivery system. Severing a middle length of each suture that connects the holder 22 to the valve member 24 permits the delivery system 110 with the holder at the distal end to be pulled free from the valve 20. However, the delivery system 110 also features a simple engagement and detachment mechanism that enables the surgeon to easily remove the system 110 from the holder 22 which remains attached to the valve 20. This detachment may be needed to replace the balloon catheter, such as if the original balloon develops a leak or for some reason does not deploy properly. This “quick-release” arrangement permits the surgeon to rapidly exchange catheters while leaving the valve 20 in place.
Finally, the prosthetic heart valve 20 is fully implanted with the guide sutures 39 knotted on the proximal face of a sewing ring 28. The guide sutures 39 are primarily for rotationally orienting the heart valve 20 as it seats against the aortic annulus and to define a plane for axial positioning. As such, the guide sutures 39 are not believed strictly necessary for securing the heart valve 20 at the annulus. Moreover, devices other than knots such as clips or cinches could be used to secure the guide sutures 39 speed up the process.
Also, the balloon 112 may have a larger distal expanded end than its proximal expanded end so as to apply more force to the free end of the anchoring skirt 26 than to the prosthetic valve member 24. In this way, the prosthetic valve member 24 and flexible leaflets therein are not subject to high expansion forces from the balloon 112.
With reference to
Another advantageous feature of the present application is a keyed engagement between delivery systems 110 and holders 22 for the same size of heart valves. In particular, the hub portion 30 of the holder 22 has an internal star-shaped bore 38 (see
Typically, the delivery system 110 is packaged separately from the heart valve 20 and holder 22, and this keying arrangement prevents misuse of the wrong delivery system. Additionally, if the balloon breaks and another delivery system must be rapidly obtained and utilized, the keying arrangement prevents the wrong delivery system from being substituted. There are typically 6-8 valve sizes in 2 millimeter increments, and thus a similar number of unique keyed couplings will be provided. Furthermore, the star-shaped pattern disclosed permits engagement at a plurality of rotational orientations. In a preferred embodiment, the user must rotate the delivery system 110 no more than 30° before the star-shaped rim of the adapter 208 mates with the internal star-shaped bore 36 of the holder 22. This is extremely beneficial if changing out the delivery system 110, because the original elongated handle shaft 130 may be bent into a particular orientation which is much easier to replicate if the keyed features do not have to be oriented in only one or two angular relations.
As mentioned, the elongated handle shaft 130 is malleable or bendable into various shapes. This bendability of the handle shaft 130 significantly enhances the ability of a surgeon to correctly position the heart valve 20 as it advances toward the annulus. Often, access passageways into the heart during a surgical procedure are somewhat confined, and may not provide a linear approach to the annulus. Accordingly, the surgeon bends the handle shaft 130 to suit the particular surgery. Various materials and constructions may be utilized to provide a malleable tube for use as the handle shaft 130. The handle shaft 130 must be axially rigid so that the user can position the heart valve in the annulus with confidence. In a preferred embodiment, an aluminum tube having a chromate (e.g., Iridite) coating is used. Aluminum is particularly well-suited for forming small tubes that can be bent without kinking, but should be coated with Iridite or the like to prevent deterioration in and reaction with the body.
A balloon inflation tube 199 and balloon extension wire 200 are formed of materials that have column strength but are relatively flexible in bending. The wire may be Nitinol while the inflation tube 199 is desirably formed of a braid reinforced thermoplastic elastomer (TPE) such as a polyether block amide known under the trade name of PEBAX® (Arkema of Colombes, France).
As the delivery system 110 may be subjected to several bends in use, care must be taken to ensure that the concentric tubes and wire do not introduce misalignment. That is, smaller diameter objects tend to travel shorter paths within larger concentric tubes, thus cause them to extend out of the distal end of the tubes after being bent. As such, the balloon inflation tube 199 is desirably closely sized to match the inner diameter of the malleable handle shaft 130. This close matching of tube sizes ensures that the axial position of the balloon 112, which is affixed to the end of the balloon inflation tube 199, does not shift much relative to the axial position of the prosthetic heart valve 20, which is affixed relative to the end of the malleable handle shaft 130. The balloon extension wire 200 has a size relative to the ID of the balloon inflation tube 199 sufficient to permit good flow of saline when filling the balloon 112.
The present application also provides an improved balloon 112 and system for deploying and removing it, as seen best in
The exemplary delivery system balloon 112 has a relatively high diameter-to-length ratio compared to other surgical balloons, such as those used to expand cardiovascular stents. This makes it particularly difficult for the balloon 112 to return to a small geometry upon deflation after deployment. Balloons of such size ratios tend to “butterfly” by forming wings that prevent removal through the valve holder without the application of high forces, which may cause damage to the valve itself. The exemplary delivery system 110 and balloon 112 include several advances from earlier heart valve delivery systems that facilitate atraumatic removal of the balloon 112. First, as mentioned above, a series of longitudinal pleats are heat set into the wall of the balloon 112 to facilitate self-collapse during deflation. Further, the distal end of the balloon 112 moves relative to the proximal end to enable lengthening of the balloon during deflation. This lengthening occurs automatically by virtue of the wire 200 which is spring-biased to stretch the balloon longitudinally. It should be noted that easy deflation and removal of the balloon 112 permits rapid replacement of the balloon catheter in case of a problem, such as insufficient inflation.
Finally,
As mentioned above, the balloon 112 desirably has a frustoconical profile that expands the anchoring skirt 26 into a frusto-conical expanded state. More typically, and as shown in
It should be noted that the flared shape of the expanded anchoring stent 26 (see
It should be mentioned that as an alternative to a balloon, a mechanical expander may be used to expand the anchoring skirt 26 shown above. For instance, a mechanical expander may include a plurality of spreadable fingers actuated by a syringe-like apparatus, as seen in U.S. Pat. No. 8,308,798, filed Dec. 10, 2009, incorporated herein. The fingers are axially fixed but capable of pivoting or flexing with respect to a barrel. The distal end of a plunger has an outer diameter that is greater than the diameter circumscribed by the inner surfaces of the spreadable fingers, such that distal movement of the plunger with respect to the barrel gradually cams the fingers outward within the coupling stent. Alternatives include mechanical fingers that are not pivotally attached to a handle attachment member. In this way, an inflation balloon causes direct radial expansion of the fingers instead of a pivoting movement. Therefore, the term “expansion catheter” pertains to balloon catheters, purely mechanical spreaders on the end of a catheter, or combinations thereof. Also, “plastically-expandable” encompasses materials that can be substantially deformed by an applied force, such as by a balloon or a mechanical spreader, to assume a different shape. Some self-expanding stents may be deformed to a degree by an applied force beyond their maximum expanded dimension, but the primary cause of the shape change is elastic rebound as opposed to a plastic deformation.
In a preferred embodiment, and as seen in the cutaway portion of
As stated previously, the completed valve member 24 shown in
One feature of the valve member 24 that is considered particularly important is the sewing ring 62 that surrounds the inflow end thereof. As will be seen, the sewing ring 62 is used to attach the anchoring skirt 26 to the valve member 24. Moreover, the sewing ring 62 presents an outward flange that contacts and outflow side of the part of annulus, while the anchoring skirt 26 expands and contracts the opposite, ventricular side of the annulus, therefore securing the heart valve 20 to the annulus from both sides. Furthermore, the presence of the sewing ring 62 provides an opportunity for the surgeon to use conventional sutures to secure the heart valve 20 to the annulus as a contingency.
The preferred sewing ring 62 defines a relatively planar upper or outflow face and an undulating lower face. Cusps of the valve structure abut the sewing ring upper face opposite locations where the lower face defines peaks. Conversely, the valve commissure posts align with locations where the sewing ring lower face defines troughs. The undulating shape of the lower face advantageously matches the anatomical contours of the aortic side of the annulus AA, that is, the supra-annular shelf. The ring 62 preferably comprises a suture-permeable material such as rolled synthetic fabric or a silicone inner core covered by a synthetic fabric. In the latter case, the silicone may be molded to define the contour of the lower face and the fabric cover conforms thereover.
Now with reference to
The general function of the anchoring skirt 26 is to provide the means to attach the prosthetic valve member 24 to the native aortic root. This attachment method is intended as an alternative to the present standard surgical method of suturing aortic valve bio-prostheses to the aortic valve annulus, and is accomplished in much less time. Further, this attachment method improves ease of use by eliminating most of not all suturing. The anchoring skirt 26 may be a pre-crimped, tapered, 316L stainless steel balloon-expandable stent, desirably covered by a polyester fabric to help seal against paravalvular leakage and promote tissue ingrowth once implanted within the annulus. The anchoring skirt 26 transitions between the tapered constricted shape of
The anchoring skirt 26 comprises an inner stent frame 80, a fabric covering 82, and a band-like lower sealing flange 84. The inner stent frame 80 will be described in greater detail below, but preferably comprises a tubular plastically-expandable member having an undulating or scalloped upper end 86. The stent frame 80 assembles within a tubular section of fabric 82 which is then drawn taut around the stent frame, inside and out, and sewn thereto to form the intermediate cloth-covered frame 88 in
A particular sequence for attaching the tubular section of fabric 82 around the stent frame 80 includes providing longitudinal suture markers (not shown) at 120° locations around the fabric to enable registration with similarly circumferentially-spaced, commissure features on the stent frame. After surrounding the stent frame 80 with the fabric 82, a series of longitudinal sutures at each of the three 120° locations secure the two components together. Furthermore, a series of stitches are provided along the undulating upper end 86 of the stent frame 80 to complete the fabric enclosure. In one embodiment, the tubular section of fabric 82 comprises PTFE cloth, although other biocompatible fabrics may be used.
Subsequently, the lower sealing flange 84 shown in
The material of the lower sealing flange 84 may vary, but preferably provides a compressible flange about the lower edge of the anchoring skirt 26. For example, the lower sealing flange 84 may be a knitted PTFE fabric in a single layer or multiple layers, Teflon, a silicone ring covered by fabric, or other similar expedients. Furthermore, the sealing flange 84 may not comprise fabric at all, but may be a hydrophilic coating, fibrin glue, or other such substance that helps prevent leakage around the outside of the anchoring skirt 26. The main functions of the fabric layers covering the frame 88 are to help prevent paravalvular leaks and provide means to securely encapsulate any Calcium nodules on the aortic valve leaflets (if left in place) and/or the aortic valve annulus. Covering the entire anchoring skirt 26 eliminates exposed metal and decreases the risk of thromboembolic events and abrasion. In a preferred embodiment, the sealing flange 84 has an axial dimension of between about 2-5 mm, and is spaced from the upper end 86 of the frame 80 by a distance that varies between 2-5 mm. The lower end of the frame may also be scalloped to follow the upper end 86, in which case the sealing flange 84 may also undulate to maintain an even distance with the upper end 86. If a knitted PTFE fabric, the sealing flange 84 desirably has a radial thickness of at least twice the thickness of the tubular fabric 82.
The anchoring skirt 26 preferably attaches to the sewing ring 62 during the manufacturing process in a way that preserves the integrity of the ring and prevents reduction of the valve's effective orifice area (EOA). Desirably, the anchoring skirt 26 will be continuously sutured to the ring 62 in a manner that maintains the contours of the ring. In this regard, sutures may be passed through apertures or eyelets 92 arrayed along the upper or first end 86 of the inner stent frame 80. Other connection solutions include prongs or hooks extending inward from the stent, ties, Velcro, snaps, adhesives, etc. Alternatively, the anchoring skirt 26 may be more rigidly connected to rigid components within the prosthetic valve member 24.
The inner stent frame 80 seen in
It should be noted that the stent frame 80 as seen in
With reference to both
The mid-section of the frame 80 has three rows of expandable struts 98 in a sawtooth pattern between axially-extending struts 100. The axially-extending struts 100 are in-phase with the peaks 93b and troughs 93a of the upper end 86 of the stent. The reinforcing ring defined by the thicker wire upper end 86 is continuous around its periphery and has a substantially constant thickness or wire diameter interrupted by the aforementioned eyelets 92. Note that the attachment sutures ensure that the peaks of the upper end 86 of the skirt 26 fit closely to the troughs of the sewing ring 62, which are located under the commissures of the valve.
The minimum ID of the upper end 86 of the covered skirt 26 will always be bigger than the ID of the prosthetic valve member 24 to which it attaches. For instance, if the upper end 86 secures to the underside of the sewing ring 62, which surrounds the support structure of the valve, it will by definition be equal to or larger than the ID of the support structure (which defines the valve orifice and corresponding labeled valve size).
The specific dimensions of the stent frame 80 for different sizes of valves are presented below in Tables I and II. Although these sizes are exemplary only, they provide trends in terms of what is believed to be desirable for ensuring that the various valve sizes are securely held at the aortic annulus and prevent paravalvular leakage.
In one embodiment, the crimp angle is between about 25-35°, and more particularly about 30°. It should be noted that as valve size increases, the height of the anchoring stent does not necessarily continue to increase. That is, there is a linear height increase between valve sizes 19-23 mm, but the height of the pre-crimped tube for valve sizes 25-27 mm is the same. Upon expansion, the portion of the stent frame 80 that is below the valleys 93a expands outward from the shape seen in
In a preferred assembly sequence, the stent frame 80 is crimped into the contracted configuration prior to covering with fabric to form the anchoring skirt 26, and prior to attaching to the valve member 24. That is, the purely conical shape shown in
Although a preferred sequence is to crimp the stent frame 80 prior to covering with cloth, the cloth-covered stent frame 80 may be tubular when attached to the valve member 24, and then crimped into the conical shape shown in
In an optional second crimping step, shown in
In a preferred embodiment, the fabric 82 immediately covering the stent 80 (inner fabric layer) comprises polytetrafluoroethylene (PTFE) cloth, such as Teflon, although other biocompatible fabrics may be used. More particularly, the fabric 82 is a PTFE flat yarn obtained from Atex Technologies Inc. of Pinebluff, N.C. Conversely, the sealing flange 84 comprises a much thicker material to provide prevention of paravalvular leakage. For instance, the sealing flange 84 is formed of a plush polymer, and made of polyethylene terephthalate (PET). More preferably, the material of the sealing flange 84 has a base yarn which is flat yarn 40/27, and a loop yarn extending therefrom made from PET 70/12 textured yarn both obtained from Atex Technologies Inc. of Pinebluff, N.C. The thickness of the sealing flange 84 material is desirably about 1.2 mm, uncompressed, while the thickness of the fabric 82 may be 50% or less of that. In alternative embodiments, different materials can be used from the covering layer 82 and the sealing layer 84, such as PTFE/cloth, cloth/cloth, or PTFE or cloth for the covering layer 82 and a swellable hydrophilic polymer such as an acrylic for the sealing layer 84.
The strip 310 is then looped with the smooth side 312 outward and the free ends sewn together to form a ring 316, as shown in
Now with reference to
With reference first to
The anchoring skirt 26 comprises the structural stent 80 having the fabric cover 82 and the sealing flange 84. In the illustrated embodiment, the sealing flange 84 comprises a plush fabric that is folded in half at the bottom with the free edges at the top sewn together. This structure is the same as the ring 318 shown in
In
Various heart valves may be utilized in combination with the delivery system components described herein, and any combination not otherwise explicitly described is contemplated. For instance,
As seen in
In contrast,
In both
Once again, the cloth-covered anchoring skirt 404 is secured at a butt joint to an inflow end of the Magna valve, such as with sutures through the stent frame of the skirt 404 and through apertures in the band structure 414. Furthermore, the lower end of the sewing ring 422 desirably overlaps the anchoring skirt 404 by a short distance and the stitching 424 extends down therebetween. This further enhances the stiffness of the assembly, thus improving seating and sealing against the aortic annulus. Although not shown, the sewing ring 422 may be annular but is desirably slightly scalloped so as to better conform to the aortic annulus. The stiff scalloped sewing ring 422 assists the surgeon in rapidly seating the prosthetic valve in place by providing a firm platform to mate against the contours of the undulating aortic annulus.
It should be noted that a sewing ring per se may not be necessary with the present heart valve as the primary function of such a component is to provide a platform through which to pass a number of anchoring sutures around the valve periphery, which is not used here except perhaps for several (e.g., 3) guide sutures. Consequently, the valve members described herein could be coupled to the anchoring skirt directly without a sewing ring. To help prevent paravalvular leaking a peripheral seal such as a fabric skirt as described above may be added in place of the sewing ring. Also, several tabs extending outward from the valve structure could be used for anchoring the guide sutures which take the place of the sewing ring for that purpose.
The system disclosed herein is also desirably used with a particular valve annulus sizing technique. The sizing apparatus (not shown) includes a catheter shaft having a compliant balloon on a distal end that can be inflated with saline. An intravascular ultrasound (IVUS) imaging probe extends through the catheter and within the compliant balloon. After preparing the patient for surgery, but prior to introduction of the delivery system 110, the balloon catheter is introduced into the valve annulus. The balloon is filled to a desired pressure, and the IVUS probe is advanced through the catheter and into the balloon. Because the balloon conforms to the anatomical cavity surrounding it, the IVUS probe measures the size of that cavity.
The advantage of being able to expand the native annulus with the expandable skirt to receive a larger valve size than would otherwise be possible with conventional surgery was mentioned above. Another way to accomplish such enlargement is to utilize a tapered dilator, such as a Hagar dilator. The conical dilator has a maximum diameter that is larger than the anticipated valve diameter. By passing the dilator into the annulus prior to installation of the valve, a larger valve may be selected. Furthermore, the larger valve temporarily fits within the annulus, but the resiliency of the tissue constricts around the valve for a more secure anchor.
While the invention has been described in its preferred embodiments, it is to be understood that the words which have been used are words of description and not of limitation. Therefore, changes may be made within the appended claims without departing from the true scope of the invention.
The present application is a continuation-in-part of U.S. patent application Ser. No. 13/167,639, filed Jun. 23, 2011, which claims priority under 35 U.S.C. §119(e) to U.S. provisional application No. 61/381,931 filed Sep. 10, 2010.
| Number | Name | Date | Kind |
|---|---|---|---|
| 3143742 | Cromie | Aug 1964 | A |
| 3320972 | High et al. | May 1967 | A |
| 3371352 | Siposs et al. | Mar 1968 | A |
| 3409013 | Berry | Nov 1968 | A |
| 3546710 | Shumakov et al. | Dec 1970 | A |
| 3574865 | Hamaker | Apr 1971 | A |
| 3628535 | Ostrowsky et al. | Dec 1971 | A |
| 3657744 | Ersek | Apr 1972 | A |
| 3686740 | Shiley | Aug 1972 | A |
| 3755823 | Hancock | Sep 1973 | A |
| 3839741 | Haller | Oct 1974 | A |
| 3997923 | Possis | Dec 1976 | A |
| 4035849 | Angell et al. | Jul 1977 | A |
| 4078468 | Civitello | Mar 1978 | A |
| 4079468 | Liotta et al. | Mar 1978 | A |
| 4084268 | Ionescu et al. | Apr 1978 | A |
| 4106129 | Carpentier et al. | Aug 1978 | A |
| 4172295 | Batten | Oct 1979 | A |
| 4217665 | Bex et al. | Aug 1980 | A |
| 4218782 | Rygg | Aug 1980 | A |
| 4259753 | Liotta et al. | Apr 1981 | A |
| RE30912 | Hancock | Apr 1982 | E |
| 4343048 | Ross et al. | Aug 1982 | A |
| 4364126 | Rosen et al. | Dec 1982 | A |
| 4388735 | Ionescu et al. | Jun 1983 | A |
| 4441216 | Ionescu et al. | Apr 1984 | A |
| 4451936 | Carpentier et al. | Jun 1984 | A |
| 4470157 | Love | Sep 1984 | A |
| 4501030 | Lane | Feb 1985 | A |
| 4506394 | Bedard | Mar 1985 | A |
| 4535483 | Klawitter et al. | Aug 1985 | A |
| 4605407 | Black et al. | Aug 1986 | A |
| 4626255 | Reichart et al. | Dec 1986 | A |
| 4629459 | Ionescu et al. | Dec 1986 | A |
| 4680031 | Alonso | Jul 1987 | A |
| 4702250 | Ovil et al. | Oct 1987 | A |
| 4705516 | Barone et al. | Nov 1987 | A |
| 4725274 | Lane et al. | Feb 1988 | A |
| 4731074 | Rousseau et al. | Mar 1988 | A |
| 4759758 | Gabbay | Jul 1988 | A |
| 4778461 | Pietsch et al. | Oct 1988 | A |
| 4790843 | Carpentier et al. | Dec 1988 | A |
| 4851000 | Gupta | Jul 1989 | A |
| 4865600 | Carpentier et al. | Sep 1989 | A |
| 4888009 | Lederman et al. | Dec 1989 | A |
| 4914097 | Oda et al. | Apr 1990 | A |
| 4960424 | Grooters | Oct 1990 | A |
| 4993428 | Arms | Feb 1991 | A |
| 5010892 | Colvin et al. | Apr 1991 | A |
| 5032128 | Alonso | Jul 1991 | A |
| 5037434 | Lane | Aug 1991 | A |
| 5147391 | Lane | Sep 1992 | A |
| 5163955 | Love et al. | Nov 1992 | A |
| 5258023 | Reger | Nov 1993 | A |
| 5290300 | Cosgrove et al. | Mar 1994 | A |
| 5316016 | Adams et al. | May 1994 | A |
| 5326370 | Love et al. | Jul 1994 | A |
| 5326371 | Love et al. | Jul 1994 | A |
| 5332402 | Teitelbaum | Jul 1994 | A |
| 5370685 | Stevens | Dec 1994 | A |
| 5376112 | Duran | Dec 1994 | A |
| 5396887 | Imran | Mar 1995 | A |
| 5397351 | Pavcnik et al. | Mar 1995 | A |
| 5411552 | Andersen et al. | May 1995 | A |
| 5413676 | Nguyen et al. | May 1995 | A |
| 5423887 | Love et al. | Jun 1995 | A |
| 5425741 | Lemp et al. | Jun 1995 | A |
| 5431676 | Dubrul et al. | Jul 1995 | A |
| 5449384 | Johnson | Sep 1995 | A |
| 5449385 | Religa et al. | Sep 1995 | A |
| 5469868 | Reger | Nov 1995 | A |
| 5476510 | Eberhardt et al. | Dec 1995 | A |
| 5488789 | Religa et al. | Feb 1996 | A |
| 5489297 | Duran | Feb 1996 | A |
| 5489298 | Love et al. | Feb 1996 | A |
| 5500016 | Fisher | Mar 1996 | A |
| 5522884 | Wright | Jun 1996 | A |
| 5531785 | Love et al. | Jul 1996 | A |
| 5533515 | Coller et al. | Jul 1996 | A |
| 5549665 | Vesely et al. | Aug 1996 | A |
| 5562729 | Purdy et al. | Oct 1996 | A |
| 5571215 | Sterman et al. | Nov 1996 | A |
| 5573007 | Bobo, Sr. | Nov 1996 | A |
| 5578076 | Krueger et al. | Nov 1996 | A |
| 5584803 | Stevens et al. | Dec 1996 | A |
| 5618307 | Donlon et al. | Apr 1997 | A |
| 5626607 | Malecki et al. | May 1997 | A |
| 5628789 | Vanney et al. | May 1997 | A |
| 5693090 | Unsworth et al. | Dec 1997 | A |
| 5695503 | Krueger et al. | Dec 1997 | A |
| 5713952 | Vanney et al. | Feb 1998 | A |
| 5716370 | Williamson, IV et al. | Feb 1998 | A |
| 5728064 | Burns et al. | Mar 1998 | A |
| 5728151 | Garrison et al. | Mar 1998 | A |
| 5735894 | Krueger et al. | Apr 1998 | A |
| 5752522 | Murphy | May 1998 | A |
| 5755782 | Love et al. | May 1998 | A |
| 5766240 | Johnson | Jun 1998 | A |
| 5776187 | Krueger et al. | Jul 1998 | A |
| 5776188 | Shepherd et al. | Jul 1998 | A |
| 5800527 | Jansen et al. | Sep 1998 | A |
| 5814097 | Sterman et al. | Sep 1998 | A |
| 5814098 | Hinnenkamp et al. | Sep 1998 | A |
| 5824064 | Taheri | Oct 1998 | A |
| 5840081 | Andersen et al. | Nov 1998 | A |
| 5848969 | Panescu et al. | Dec 1998 | A |
| 5855563 | Kaplan et al. | Jan 1999 | A |
| 5855601 | Bessler et al. | Jan 1999 | A |
| 5865801 | Houser | Feb 1999 | A |
| 5891160 | Williamson, IV et al. | Apr 1999 | A |
| 5895420 | Mirsch, II et al. | Apr 1999 | A |
| 5902308 | Murphy | May 1999 | A |
| 5908450 | Gross et al. | Jun 1999 | A |
| 5919147 | Jain | Jul 1999 | A |
| 5921934 | Teo | Jul 1999 | A |
| 5921935 | Hickey | Jul 1999 | A |
| 5924984 | Rao | Jul 1999 | A |
| 5957949 | Leonhardt et al. | Sep 1999 | A |
| 5972004 | Williamson, IV et al. | Oct 1999 | A |
| 5984959 | Robertson et al. | Nov 1999 | A |
| 5984973 | Girard et al. | Nov 1999 | A |
| 6010531 | Donlon et al. | Jan 2000 | A |
| 6042607 | Williamson, IV et al. | Mar 2000 | A |
| 6059827 | Fenton, Jr. | May 2000 | A |
| 6066160 | Colvin et al. | May 2000 | A |
| 6074418 | Buchanan et al. | Jun 2000 | A |
| 6081737 | Shah | Jun 2000 | A |
| 6083179 | Oredsson | Jul 2000 | A |
| 6099475 | Seward et al. | Aug 2000 | A |
| 6106550 | Magovern et al. | Aug 2000 | A |
| 6110200 | Hinnenkamp | Aug 2000 | A |
| 6117091 | Young et al. | Sep 2000 | A |
| 6162233 | Williamson, IV et al. | Dec 2000 | A |
| 6168614 | Andersen et al. | Jan 2001 | B1 |
| 6176877 | Buchanan et al. | Jan 2001 | B1 |
| 6197054 | Hamblin, Jr. et al. | Mar 2001 | B1 |
| 6217611 | Klostermeyer | Apr 2001 | B1 |
| 6231561 | Frazier et al. | May 2001 | B1 |
| 6241765 | Griffin et al. | Jun 2001 | B1 |
| 6245102 | Jayaraman | Jun 2001 | B1 |
| 6283127 | Sterman et al. | Sep 2001 | B1 |
| 6287339 | Vazquez et al. | Sep 2001 | B1 |
| 6290674 | Roue et al. | Sep 2001 | B1 |
| 6312447 | Grimes | Nov 2001 | B1 |
| 6312465 | Griffin et al. | Nov 2001 | B1 |
| 6328727 | Frazier et al. | Dec 2001 | B1 |
| 6371983 | Lane | Apr 2002 | B1 |
| 6402780 | Williamson, IV et al. | Jun 2002 | B2 |
| 6425916 | Garrison et al. | Jul 2002 | B1 |
| 6440164 | DiMatteo et al. | Aug 2002 | B1 |
| 6447551 | Goldmann | Sep 2002 | B1 |
| 6454799 | Schreck | Sep 2002 | B1 |
| 6458153 | Bailey et al. | Oct 2002 | B1 |
| 6468305 | Otte | Oct 2002 | B1 |
| 6530952 | Vesely | Mar 2003 | B2 |
| 6558429 | Taylor | May 2003 | B2 |
| 6569196 | Vesely | May 2003 | B1 |
| 6585766 | Huynh et al. | Jul 2003 | B1 |
| 6652578 | Bailey et al. | Nov 2003 | B2 |
| 6682559 | Myers et al. | Jan 2004 | B2 |
| 6685739 | DiMatteo et al. | Feb 2004 | B2 |
| 6719789 | Cox | Apr 2004 | B2 |
| 6730118 | Spenser et al. | May 2004 | B2 |
| 6733525 | Pease et al. | May 2004 | B2 |
| 6764508 | Roehe et al. | Jul 2004 | B1 |
| 6767362 | Schreck | Jul 2004 | B2 |
| 6786925 | Schoon et al. | Sep 2004 | B1 |
| 6790229 | Berreklouw | Sep 2004 | B1 |
| 6790230 | Beyersdorf et al. | Sep 2004 | B2 |
| 6805711 | Quijano et al. | Oct 2004 | B2 |
| 6846325 | Liddicoat | Jan 2005 | B2 |
| 6893459 | Macoviak | May 2005 | B1 |
| 6893460 | Spenser et al. | May 2005 | B2 |
| 6908481 | Cribier | Jun 2005 | B2 |
| 6936067 | Buchanan | Aug 2005 | B2 |
| 6939365 | Fogarty et al. | Sep 2005 | B1 |
| 6974476 | McGuckin, Jr. et al. | Dec 2005 | B2 |
| 7011681 | Vesely | Mar 2006 | B2 |
| 7018406 | Seguin et al. | Mar 2006 | B2 |
| 7025780 | Gabbay | Apr 2006 | B2 |
| 7070616 | Majercak et al. | Jul 2006 | B2 |
| 7081131 | Thornton | Jul 2006 | B2 |
| 7097659 | Woolfson et al. | Aug 2006 | B2 |
| 7101396 | Artof et al. | Sep 2006 | B2 |
| 7147663 | Berg et al. | Dec 2006 | B1 |
| 7153324 | Case et al. | Dec 2006 | B2 |
| 7172625 | Shu et al. | Feb 2007 | B2 |
| 7195641 | Palmaz et al. | Mar 2007 | B2 |
| 7201771 | Lane | Apr 2007 | B2 |
| 7201772 | Schwammenthal et al. | Apr 2007 | B2 |
| 7238200 | Lee et al. | Jul 2007 | B2 |
| 7252682 | Seguin | Aug 2007 | B2 |
| 7261732 | Justino | Aug 2007 | B2 |
| 7311730 | Gabbay | Dec 2007 | B2 |
| RE40377 | Williamson, IV et al. | Jun 2008 | E |
| 7422603 | Lane | Sep 2008 | B2 |
| 7429269 | Schwammenthal et al. | Sep 2008 | B2 |
| 7442204 | Schwammenthal et al. | Oct 2008 | B2 |
| 7445630 | Lashinski et al. | Nov 2008 | B2 |
| 7468073 | Johnson et al. | Dec 2008 | B2 |
| 7470285 | Nugent et al. | Dec 2008 | B2 |
| 7513909 | Lane et al. | Apr 2009 | B2 |
| 7534261 | Friedman | May 2009 | B2 |
| 7556647 | Drews et al. | Jul 2009 | B2 |
| 7569072 | Berg et al. | Aug 2009 | B2 |
| 7578843 | Shu | Aug 2009 | B2 |
| 7585321 | Cribier | Sep 2009 | B2 |
| 7597711 | Drews et al. | Oct 2009 | B2 |
| 7611535 | Woolfson et al. | Nov 2009 | B2 |
| 7682390 | Seguin | Mar 2010 | B2 |
| 8308798 | Pintor et al. | Nov 2012 | B2 |
| 8348998 | Pintor et al. | Jan 2013 | B2 |
| 8353953 | Giannetti et al. | Jan 2013 | B2 |
| 20010021872 | Bailey et al. | Sep 2001 | A1 |
| 20010039435 | Roue et al. | Nov 2001 | A1 |
| 20010039436 | Frazier et al. | Nov 2001 | A1 |
| 20010041914 | Frazier et al. | Nov 2001 | A1 |
| 20010041915 | Roue et al. | Nov 2001 | A1 |
| 20010049492 | Frazier et al. | Dec 2001 | A1 |
| 20020026238 | Lane et al. | Feb 2002 | A1 |
| 20020032481 | Gabbay | Mar 2002 | A1 |
| 20020058995 | Stevens | May 2002 | A1 |
| 20020123802 | Snyders | Sep 2002 | A1 |
| 20020138138 | Yang | Sep 2002 | A1 |
| 20020151970 | Garrison et al. | Oct 2002 | A1 |
| 20020188348 | DiMatteo et al. | Dec 2002 | A1 |
| 20020198594 | Schreck | Dec 2002 | A1 |
| 20030014104 | Cribier | Jan 2003 | A1 |
| 20030023300 | Bailey et al. | Jan 2003 | A1 |
| 20030023303 | Palmaz et al. | Jan 2003 | A1 |
| 20030036795 | Andersen et al. | Feb 2003 | A1 |
| 20030040792 | Gabbay | Feb 2003 | A1 |
| 20030055495 | Pease et al. | Mar 2003 | A1 |
| 20030109924 | Cribier | Jun 2003 | A1 |
| 20030114913 | Spenser et al. | Jun 2003 | A1 |
| 20030130729 | Paniagua et al. | Jul 2003 | A1 |
| 20030149478 | Figulla et al. | Aug 2003 | A1 |
| 20030167089 | Lane | Sep 2003 | A1 |
| 20030236568 | Hojeibane et al. | Dec 2003 | A1 |
| 20040019374 | Hojeibane et al. | Jan 2004 | A1 |
| 20040034411 | Quijano et al. | Feb 2004 | A1 |
| 20040044406 | Woolfson et al. | Mar 2004 | A1 |
| 20040106976 | Bailey et al. | Jun 2004 | A1 |
| 20040122514 | Fogarty et al. | Jun 2004 | A1 |
| 20040122516 | Fogarty et al. | Jun 2004 | A1 |
| 20040167573 | Williamson et al. | Aug 2004 | A1 |
| 20040186563 | Lobbi | Sep 2004 | A1 |
| 20040186565 | Schreck | Sep 2004 | A1 |
| 20040193261 | Berreklouw | Sep 2004 | A1 |
| 20040206363 | McCarthy et al. | Oct 2004 | A1 |
| 20040210304 | Seguin et al. | Oct 2004 | A1 |
| 20040210307 | Khairkhahan | Oct 2004 | A1 |
| 20040225355 | Stevens | Nov 2004 | A1 |
| 20040236411 | Sarac et al. | Nov 2004 | A1 |
| 20040260389 | Case et al. | Dec 2004 | A1 |
| 20040260390 | Sarac et al. | Dec 2004 | A1 |
| 20050010285 | Lambrecht et al. | Jan 2005 | A1 |
| 20050027348 | Case et al. | Feb 2005 | A1 |
| 20050033398 | Seguin | Feb 2005 | A1 |
| 20050043760 | Fogarty et al. | Feb 2005 | A1 |
| 20050043790 | Seguin | Feb 2005 | A1 |
| 20050060029 | Le et al. | Mar 2005 | A1 |
| 20050065594 | DiMatteo et al. | Mar 2005 | A1 |
| 20050065614 | Stinson | Mar 2005 | A1 |
| 20050075584 | Cali | Apr 2005 | A1 |
| 20050075713 | Biancucci et al. | Apr 2005 | A1 |
| 20050075717 | Nguyen et al. | Apr 2005 | A1 |
| 20050075718 | Nguyen et al. | Apr 2005 | A1 |
| 20050075719 | Bergheim | Apr 2005 | A1 |
| 20050075720 | Nguyen et al. | Apr 2005 | A1 |
| 20050075724 | Svanidze et al. | Apr 2005 | A1 |
| 20050080454 | Drews et al. | Apr 2005 | A1 |
| 20050096738 | Cali et al. | May 2005 | A1 |
| 20050137682 | Justino | Jun 2005 | A1 |
| 20050137686 | Salahieh et al. | Jun 2005 | A1 |
| 20050137687 | Salahieh et al. | Jun 2005 | A1 |
| 20050137688 | Salahieh et al. | Jun 2005 | A1 |
| 20050137689 | Salahieh et al. | Jun 2005 | A1 |
| 20050137690 | Salahieh et al. | Jun 2005 | A1 |
| 20050137691 | Salahieh et al. | Jun 2005 | A1 |
| 20050137692 | Haug et al. | Jun 2005 | A1 |
| 20050137694 | Haug et al. | Jun 2005 | A1 |
| 20050137695 | Salahieh et al. | Jun 2005 | A1 |
| 20050137702 | Haug et al. | Jun 2005 | A1 |
| 20050151970 | DeGeorge et al. | Jul 2005 | A1 |
| 20050159811 | Lane | Jul 2005 | A1 |
| 20050165477 | Anduiza et al. | Jul 2005 | A1 |
| 20050165479 | Drews et al. | Jul 2005 | A1 |
| 20050182483 | Osborne et al. | Aug 2005 | A1 |
| 20050182486 | Gabbay | Aug 2005 | A1 |
| 20050192665 | Spenser et al. | Sep 2005 | A1 |
| 20050203616 | Cribier | Sep 2005 | A1 |
| 20050203617 | Forster et al. | Sep 2005 | A1 |
| 20050203618 | Sharkawy et al. | Sep 2005 | A1 |
| 20050216079 | MaCoviak | Sep 2005 | A1 |
| 20050222674 | Paine | Oct 2005 | A1 |
| 20050234546 | Nugent et al. | Oct 2005 | A1 |
| 20050240259 | Sisken et al. | Oct 2005 | A1 |
| 20050240263 | Fogarty et al. | Oct 2005 | A1 |
| 20050251252 | Stobie | Nov 2005 | A1 |
| 20050261765 | Liddicoat | Nov 2005 | A1 |
| 20050283231 | Haug et al. | Dec 2005 | A1 |
| 20060025857 | Bergheim et al. | Feb 2006 | A1 |
| 20060052867 | Revuelta et al. | Mar 2006 | A1 |
| 20060058871 | Zakay et al. | Mar 2006 | A1 |
| 20060058872 | Salahieh et al. | Mar 2006 | A1 |
| 20060074484 | Huber | Apr 2006 | A1 |
| 20060085060 | Campbell | Apr 2006 | A1 |
| 20060095125 | Chinn et al. | May 2006 | A1 |
| 20060122634 | Ino et al. | Jun 2006 | A1 |
| 20060122692 | Gilad et al. | Jun 2006 | A1 |
| 20060136054 | Berg et al. | Jun 2006 | A1 |
| 20060149360 | Schwammenthal et al. | Jul 2006 | A1 |
| 20060154230 | Cunanan et al. | Jul 2006 | A1 |
| 20060161249 | Realyvasquez et al. | Jul 2006 | A1 |
| 20060167543 | Bailey et al. | Jul 2006 | A1 |
| 20060195183 | Navia et al. | Aug 2006 | A1 |
| 20060195184 | Lane et al. | Aug 2006 | A1 |
| 20060195185 | Lane et al. | Aug 2006 | A1 |
| 20060195186 | Drews et al. | Aug 2006 | A1 |
| 20060207031 | Cunanan et al. | Sep 2006 | A1 |
| 20060229708 | Powell et al. | Oct 2006 | A1 |
| 20060235508 | Lane et al. | Oct 2006 | A1 |
| 20060241745 | Solem | Oct 2006 | A1 |
| 20060246888 | Bender et al. | Nov 2006 | A1 |
| 20060253191 | Salahieh et al. | Nov 2006 | A1 |
| 20060259134 | Schwammenthal et al. | Nov 2006 | A1 |
| 20060259135 | Navia et al. | Nov 2006 | A1 |
| 20060259136 | Nguyen et al. | Nov 2006 | A1 |
| 20060259137 | Artof et al. | Nov 2006 | A1 |
| 20060265056 | Nguyen et al. | Nov 2006 | A1 |
| 20060271172 | Tehrani | Nov 2006 | A1 |
| 20060271175 | Woolfson et al. | Nov 2006 | A1 |
| 20060287717 | Rowe et al. | Dec 2006 | A1 |
| 20060287719 | Rowe et al. | Dec 2006 | A1 |
| 20070005129 | Damm et al. | Jan 2007 | A1 |
| 20070010876 | Salahieh et al. | Jan 2007 | A1 |
| 20070010877 | Salahieh et al. | Jan 2007 | A1 |
| 20070016285 | Lane et al. | Jan 2007 | A1 |
| 20070016286 | Herrmann et al. | Jan 2007 | A1 |
| 20070016288 | Gurskis et al. | Jan 2007 | A1 |
| 20070043435 | Seguin et al. | Feb 2007 | A1 |
| 20070078509 | Lotfy | Apr 2007 | A1 |
| 20070078510 | Ryan | Apr 2007 | A1 |
| 20070100440 | Figulla et al. | May 2007 | A1 |
| 20070129794 | Realyvasquez | Jun 2007 | A1 |
| 20070142906 | Figulla et al. | Jun 2007 | A1 |
| 20070142907 | Moaddeb et al. | Jun 2007 | A1 |
| 20070150053 | Gurskis et al. | Jun 2007 | A1 |
| 20070156233 | Kapadia et al. | Jul 2007 | A1 |
| 20070162103 | Case et al. | Jul 2007 | A1 |
| 20070162107 | Haug et al. | Jul 2007 | A1 |
| 20070162111 | Fukamachi et al. | Jul 2007 | A1 |
| 20070179604 | Lane | Aug 2007 | A1 |
| 20070185565 | Schwammenthal et al. | Aug 2007 | A1 |
| 20070198097 | Zegdi | Aug 2007 | A1 |
| 20070203575 | Forster et al. | Aug 2007 | A1 |
| 20070203576 | Lee et al. | Aug 2007 | A1 |
| 20070213813 | Von Segesser et al. | Sep 2007 | A1 |
| 20070225801 | Drews et al. | Sep 2007 | A1 |
| 20070233237 | Krivoruchko | Oct 2007 | A1 |
| 20070239266 | Birdsall | Oct 2007 | A1 |
| 20070239269 | Dolan et al. | Oct 2007 | A1 |
| 20070239273 | Allen | Oct 2007 | A1 |
| 20070244558 | Machiraju | Oct 2007 | A1 |
| 20070255398 | Yang et al. | Nov 2007 | A1 |
| 20070260305 | Drews et al. | Nov 2007 | A1 |
| 20070265701 | Gurskis et al. | Nov 2007 | A1 |
| 20070270944 | Bergheim et al. | Nov 2007 | A1 |
| 20070282436 | Pinchuk | Dec 2007 | A1 |
| 20070288089 | Gurskis et al. | Dec 2007 | A1 |
| 20080021546 | Patz et al. | Jan 2008 | A1 |
| 20080033543 | Gurskis et al. | Feb 2008 | A1 |
| 20080065198 | Quintessenza | Mar 2008 | A1 |
| 20080082161 | Woo | Apr 2008 | A1 |
| 20080119875 | Ino et al. | May 2008 | A1 |
| 20080281411 | Berreklouw | Nov 2008 | A1 |
| 20080319543 | Lane | Dec 2008 | A1 |
| 20090036903 | Ino et al. | Feb 2009 | A1 |
| 20090192599 | Lane et al. | Jul 2009 | A1 |
| 20090192602 | Kuehn | Jul 2009 | A1 |
| 20090192603 | Ryan | Jul 2009 | A1 |
| 20090192604 | Gloss | Jul 2009 | A1 |
| 20090192605 | Gloss et al. | Jul 2009 | A1 |
| 20090192606 | Gloss et al. | Jul 2009 | A1 |
| 20100161036 | Pintor et al. | Jun 2010 | A1 |
| 20100292784 | Giannetti et al. | Nov 2010 | A1 |
| 20100331972 | Pintor et al. | Dec 2010 | A1 |
| 20110147251 | Hodshon et al. | Jun 2011 | A1 |
| 20120065729 | Pintor et al. | Mar 2012 | A1 |
| Number | Date | Country |
|---|---|---|
| 2356656 | Jan 2000 | CN |
| 0084395 | Jul 1983 | EP |
| 0096721 | Dec 1983 | EP |
| 0125393 | Nov 1984 | EP |
| 0143246 | Jun 1985 | EP |
| 0179562 | Apr 1986 | EP |
| 1171059 | Jan 2002 | EP |
| 2056023 | Mar 1981 | GB |
| 2069843 | Sep 1981 | GB |
| 2254254 | Oct 1992 | GB |
| 2279134 | Dec 1994 | GB |
| 116573 | Jul 1985 | SU |
| 1697790 | Dec 1991 | SU |
| 8900840 | Feb 1989 | WO |
| 9115167 | Oct 1991 | WO |
| 9212690 | Aug 1992 | WO |
| 9213502 | Aug 1992 | WO |
| 9219184 | Nov 1992 | WO |
| 9219185 | Nov 1992 | WO |
| 9517139 | Jun 1995 | WO |
| 9528899 | Nov 1995 | WO |
| 9640006 | Dec 1996 | WO |
| 9709933 | Mar 1997 | WO |
| 9709944 | Mar 1997 | WO |
| 9724871 | Jul 1997 | WO |
| 9727799 | Aug 1997 | WO |
| 9741801 | Nov 1997 | WO |
| 9742871 | Nov 1997 | WO |
| 9806329 | Feb 1998 | WO |
| 9911201 | Mar 1999 | WO |
| 9915112 | Apr 1999 | WO |
| 9951169 | Oct 1999 | WO |
| 0032105 | Jun 2000 | WO |
| 0040176 | Jul 2000 | WO |
| 0060995 | Oct 2000 | WO |
| 0154624 | Aug 2001 | WO |
| 0154625 | Aug 2001 | WO |
| 02076347 | Oct 2002 | WO |
| 2006086135 | Aug 2006 | WO |
| Entry |
|---|
| Krakow, “3F Therapeutics, Inc. Announces the First Clinical Implantation of the 3F Enable Aortic Heart Valve, a Patented, Sutureless Implantation, Replacement Heart Valve Intended to Save Valuable Surgery Time and Reduce Time Related Complications . . . ” Healthcare Sales & Marketing Network News Feed, Jan. 18, 2005, pp. 1-2. |
| Sadowski, Jerzy; Kapelak, Boguslaw; Bartus, Krzysztof, “Sutureless Heart Valve Implantation—A Case Study,” Touch Briefings, 2005, pp. 48-50. |
| Number | Date | Country | |
|---|---|---|---|
| 20130190862 A1 | Jul 2013 | US |
| Number | Date | Country | |
|---|---|---|---|
| 61381931 | Sep 2010 | US |
| Number | Date | Country | |
|---|---|---|---|
| Parent | 13167639 | Jun 2011 | US |
| Child | 13797591 | US |
